Free Trial
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel Free ATRA Stock Alerts

Atara Biotherapeutics (ATRA) Financials

Atara Biotherapeutics logo
$9.56 +0.25 (+2.69%)
As of 10/14/2026 04:00 PM Eastern
Compare
Annual Income Statements for Atara Biotherapeutics

Annual Income Statements for Atara Biotherapeutics

This table shows Atara Biotherapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -57 -79 -119 -231 -291 -307 -340 -228 -276 -85 33
Consolidated Net Income / (Loss)		 -57 -79 -119 -231 -291 -307 -340 -228 -276 -85 33
Net Income / (Loss) Continuing Operations		 -57 -79 -119 -231 -291 -307 -340 -228 -276 -85 33
Total Pre-Tax Income 		-57 -79 -120 -231 -291 -307 -340 -228 -276 -85 33
Total Operating Income		 -58 -81 -122 -237 -296 -309 -340 -281 -276 -83 36
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 20 64 8.57 129 121
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 20 64 8.57 129 121
Operating Revenue		 - - - - 0.00 - 20 64 8.57 129 121
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 58 81 122 237 296 309 361 344 285 212 85
Selling, General & Admin Expense		 17 25 40 70 80 64 79 72 51 40 26
Research & Development Expense		 42 57 81 167 216 245 282 273 225 151 37
Other Operating Expenses / (Income)		 - - - - - 0.00 - - 8.89 21 21
Total Other Income / (Expense), net		 1.22 2.20 2.03 6.37 4.72 2.45 0.37 52 -0.11 -1.98 -3.14
Interest Expense		 - - - - - - - 0.37 5.29 4.62 3.79
Interest & Investment Income		 - - - - - - - 3.06 5.43 2.11 0.68
Other Income / (Expense), net		 1.22 2.20 2.03 6.37 4.72 2.45 0.37 50 -0.25 0.53 -0.03
Income Tax Expense		 -0.01 0.01 -0.01 -0.04 0.01 0.02 0.05 0.01 0.02 -0.01 0.03
Basic Earnings per Share		 ($2.24) ($2.75) ($4.00) ($5.27) ($5.67) ($4.15) ($3.63) ($2.24) ($65.19) ($11.41) $2.61
Weighted Average Basic Shares Outstanding		 25.58M 28.73M 29.86M 43.81M 51.31M 73.97M 93.67M 101.99M 4.24M 7.49M 12.54M
Diluted Earnings per Share		 ($2.24) ($2.75) ($4.00) ($5.27) ($5.67) ($4.15) ($3.63) ($2.24) ($65.19) ($11.41) $2.57
Weighted Average Diluted Shares Outstanding		 25.58M 28.73M 29.86M 43.81M 51.31M 73.97M 93.67M 101.99M 4.24M 7.49M 12.72M
Weighted Average Basic & Diluted Shares Outstanding		 25.58M 28.73M 29.86M 43.81M 51.31M 73.97M 93.67M 95.93M 119.36M 5.86M 8.18M

Quarterly Income Statements for Atara Biotherapeutics

This table shows Atara Biotherapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -60 -32 -19 -22 -13 38 2.39 -4.30 -3.41 -4.15 -4.83
Consolidated Net Income / (Loss)		 -60 -32 -19 -22 -13 38 2.39 -4.30 -3.41 -4.15 -4.83
Net Income / (Loss) Continuing Operations		 -60 -32 -19 -22 -13 38 2.39 -4.30 -3.41 -4.15 -4.83
Total Pre-Tax Income 		-60 -32 -19 -22 -13 38 2.39 -4.28 -3.41 -4.15 -4.83
Total Operating Income		 -60 -31 -18 -22 -12 39 3.20 -3.57 -2.56 -3.37 -4.72
Total Gross Profit		 4.25 27 29 40 33 98 18 3.45 1.60 0.52 0.63
Total Revenue		 4.25 27 29 40 33 98 18 3.45 1.60 0.52 0.63
Operating Revenue		 4.25 27 29 40 33 98 18 3.45 1.60 0.52 0.63
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 64 59 47 62 45 59 14 7.03 4.16 3.89 5.35
Selling, General & Admin Expense		 11 11 8.91 10 9.44 11 6.51 3.99 4.28 3.60 3.81
Research & Development Expense		 50 46 33 44 29 27 7.31 2.93 -0.22 0.16 1.35
Other Operating Expenses / (Income)		 - 1.99 4.63 7.60 6.80 20 0.55 0.12 0.10 0.12 0.19
Total Other Income / (Expense), net		 -0.48 -0.48 -0.82 -0.17 -0.51 -0.79 -0.81 -0.70 -0.84 -0.78 -0.11
Interest Expense		 1.18 1.15 1.26 1.18 1.02 1.02 0.97 0.91 0.89 0.83 0.19
Interest & Investment Income		 0.71 0.60 0.45 0.46 0.60 0.24 0.14 0.20 0.10 0.05 0.08
Other Income / (Expense), net		 -0.01 0.07 -0.01 0.56 -0.09 -0.01 0.02 0.00 -0.05 0.00 0.00
Income Tax Expense		 0.01 0.02 0.00 -0.02 -0.02 0.00 0.00 0.03 - 0.00 0.00
Basic Earnings per Share		 ($14.27) ($5.65) ($3.10) ($2.93) ($1.70) $3.53 $0.20 ($0.32) ($0.27) ($0.29) ($0.32)
Weighted Average Basic Shares Outstanding		 4.24M 5.62M 6.14M 7.47M 7.49M 10.76M 12.20M 13.56M 12.54M 14.08M 15.03M
Diluted Earnings per Share		 ($14.27) ($5.65) ($3.10) ($2.93) ($1.70) $3.50 $0.19 ($0.32) ($0.27) ($0.29) ($0.32)
Weighted Average Diluted Shares Outstanding		 4.24M 5.62M 6.14M 7.47M 7.49M 10.85M 12.31M 13.56M 12.72M 14.08M 15.03M
Weighted Average Basic & Diluted Shares Outstanding		 119.36M 120.42M 4.92M 5.76M 5.86M 5.96M 7.02M 7.21M 8.18M 9.01M 10.04M

Annual Cash Flow Statements for Atara Biotherapeutics

This table details how cash moves in and out of Atara Biotherapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 1.85 24 33 -19 14 126 -94 -14 -67 -0.81 -17
Net Cash From Operating Activities		 -37 -60 -88 -180 -236 -181 -221 -270 -193 -69 -51
Net Cash From Continuing Operating Activities		 -37 -60 -86 -180 -236 -181 -221 -270 -193 -69 -51
Net Income / (Loss) Continuing Operations		 -57 -79 -119 -231 -291 -307 -340 -228 -276 -85 33
Consolidated Net Income / (Loss)		 -57 -79 -119 -231 -291 -307 -340 -228 -276 -85 33
Depreciation Expense		 0.05 0.38 0.96 3.73 7.07 8.33 9.35 5.65 4.83 5.05 2.12
Amortization Expense		 3.47 2.58 0.73 -1.89 -1.33 0.83 1.77 1.02 0.79 -0.24 0.26
Non-Cash Adjustments To Reconcile Net Income		 15 14 26 49 42 60 52 16 46 22 12
Changes in Operating Assets and Liabilities, net		 1.90 1.98 5.60 -0.20 7.21 57 57 -65 32 -11 -98
Net Cash From Investing Activities		 -220 84 100 -196 60 -121 22 203 124 8.62 18
Net Cash From Continuing Investing Activities		 -220 84 100 -196 60 -121 22 203 124 8.62 18
Purchase of Property, Plant & Equipment		 -0.29 -3.02 -20 -36 -5.73 -4.51 -11 -4.19 -1.22 -0.25 0.00
Purchase of Investments		 -380 -305 -176 -466 -270 -426 -301 -181 -84 -20 -7.89
Sale of Property, Plant & Equipment		 - - 0.00 0.00 0.16 - - 0.00 0.03 0.00 0.95
Sale and/or Maturity of Investments		 160 392 297 306 336 310 334 293 209 29 25
Net Cash From Financing Activities		 259 0.51 20 358 189 428 104 53 2.01 59 16
Net Cash From Continuing Financing Activities		 259 0.51 20 358 189 428 104 53 2.01 59 16
Repayment of Debt		 - 0.00 0.00 0.00 -0.49 -0.17 -0.02 -0.19 -0.96 -0.01 -0.00
Issuance of Common Equity		 0.44 0.60 20 72 196 430 105 24 3.06 60 16
Other Financing Activities, net		 259 -0.09 -0.36 285 -6.70 -1.91 -1.50 29 -0.09 -0.89 -0.25
Cash Interest Paid		 - 0.00 0.00 0.24 0.05 0.06 0.03 0.34 0.45 0.69 0.29
Cash Income Taxes Paid		 0.00 0.01 0.00 0.00 0.00 0.01 0.02 0.02 0.00 0.02 0.19

Quarterly Cash Flow Statements for Atara Biotherapeutics

This table details how cash moves in and out of Atara Biotherapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -39 9.25 -3.77 15 -21 -11 2.92 -11 2.74 -0.12 -5.14
Net Cash From Operating Activities		 -50 -30 -11 -3.99 -24 -28 -7.32 -9.79 -5.70 -3.07 -3.34
Net Cash From Continuing Operating Activities		 -50 -30 -11 -3.99 -24 -28 -7.32 -9.79 -5.70 -3.07 -3.34
Net Income / (Loss) Continuing Operations		 -60 -32 -19 -22 -13 38 2.39 -4.30 -3.41 -4.15 -4.83
Consolidated Net Income / (Loss)		 -60 -32 -19 -22 -13 38 2.39 -4.30 -3.41 -4.15 -4.83
Depreciation Expense		 1.21 1.39 1.33 1.23 1.10 1.80 0.24 0.04 0.05 0.03 0.01
Amortization Expense		 2.11 0.04 -0.01 -0.06 -0.21 0.26 -0.00 -0.08 0.08 0.00 -0.03
Non-Cash Adjustments To Reconcile Net Income		 8.68 9.34 -6.74 8.01 11 4.47 7.28 -5.11 4.91 1.47 0.61
Changes in Operating Assets and Liabilities, net		 -1.96 -8.62 14 8.73 -23 -73 -17 -0.33 -7.33 -0.43 0.90
Net Cash From Investing Activities		 9.94 15 7.20 -17 3.38 17 -5.07 -2.42 8.44 0.00 -6.63
Net Cash From Continuing Investing Activities		 9.94 15 7.20 -17 3.38 17 -5.07 -2.42 8.44 0.00 -6.63
Net Cash From Financing Activities		 1.51 24 -0.32 36 -0.33 -0.25 15 1.05 -0.00 2.95 4.83
Net Cash From Continuing Financing Activities		 1.51 24 -0.32 36 -0.33 -0.25 15 1.05 -0.00 2.95 4.83
Issuance of Common Equity		 1.73 24 -0.09 36 -0.09 0.00 15 1.05 -0.00 2.95 4.83
Cash Interest Paid		 0.12 0.11 0.25 0.14 0.19 0.07 0.05 0.05 0.12 0.11 0.12

Annual Balance Sheets for Atara Biotherapeutics

This table presents Atara Biotherapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 325 264 218 392 343 588 468 376 166 109 20
Total Current Assets		 325 261 172 321 273 523 385 295 102 65 12
Cash & Equivalents		 24 48 79 61 74 200 106 93 26 25 8.48
Short-Term Investments		 297 208 87 249 185 300 265 150 26 17 0.00
Accounts Receivable		 - - - - 0.00 1.25 0.99 40 34 1.48 1.25
Other Current Assets		 - - - - - - 12 10 6.18 10 2.48
Plant, Property, & Equipment, net		 0.27 3.26 44 69 54 51 54 6.30 3.86 1.29 0.07
Total Noncurrent Assets		 0.11 0.10 1.46 1.77 16 14 30 75 60 43 7.95
Other Noncurrent Operating Assets		 0.11 0.10 1.46 1.77 16 14 30 75 60 43 7.95
Total Liabilities & Shareholders' Equity		 325 264 218 392 343 588 468 376 166 109 20
Total Liabilities		 9.88 10 40 53 52 126 189 250 265 206 59
Total Current Liabilities		 9.71 9.68 28 40 37 83 106 79 142 135 15
Accounts Payable		 1.45 2.78 15 3.72 7.96 7.12 17 6.87 3.68 4.37 0.13
Accrued Expenses		 5.64 2.41 4.01 19 8.34 16 13 25 17 7.98 0.08
Current Deferred Revenue		 - - - - 0.00 33 41 8.00 78 95 0.72
Current Employee Benefit Liabilities		 2.62 3.75 5.66 11 15 20 25 18 12 6.59 1.27
Other Current Liabilities		 - 0.74 3.27 6.41 5.73 6.06 9.06 21 32 21 13
Total Noncurrent Liabilities		 0.17 0.50 12 13 15 43 83 171 123 72 44
Other Noncurrent Operating Liabilities		 0.17 0.50 12 13 15 15 27 94 85 72 44
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 315 254 178 339 291 462 280 127 -99 -97 -39
Total Preferred & Common Equity		 315 254 178 339 291 462 280 127 -99 -97 -39
Total Common Equity		 315 254 178 339 291 462 280 127 -99 -97 -39
Common Stock		 414 431 475 867 1,109 1,587 1,745 1,822 1,870 1,957 1,983
Retained Earnings		 -98 -177 -297 -527 -818 -1,125 -1,465 -1,693 -1,969 -2,055 -2,022
Accumulated Other Comprehensive Income / (Loss)		 -0.52 -0.18 -0.15 -0.34 0.22 0.30 -0.37 -2.07 -0.20 0.01 0.00

Quarterly Balance Sheets for Atara Biotherapeutics

This table presents Atara Biotherapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 189 165 117 143 62 37 30 20 21
Total Current Assets		 119 106 62 92 27 25 18 12 14
Cash & Equivalents		 65 35 31 46 14 17 5.74 8.36 3.22
Short-Term Investments		 38 11 3.98 21 0.00 5.42 7.97 - 6.65
Accounts Receivable		 0.16 36 2.42 1.34 8.88 0.00 1.91 0.00 0.32
Other Current Assets		 9.39 8.13 5.80 9.21 4.32 2.45 2.81 3.81 3.34
Plant, Property, & Equipment, net		 4.63 2.99 2.32 1.66 0.29 0.18 0.15 0.06 0.04
Total Noncurrent Assets		 65 56 53 49 35 12 12 7.77 7.45
Other Noncurrent Operating Assets		 65 56 53 49 35 12 12 7.77 7.45
Total Liabilities & Shareholders' Equity		 189 165 117 143 62 37 30 20 21
Total Liabilities		 240 264 228 233 117 72 67 57 58
Total Current Liabilities		 79 181 148 156 48 15 18 5.65 6.85
Accounts Payable		 6.51 2.85 5.25 2.15 1.38 1.76 0.32 0.64 0.82
Accrued Expenses		 24 16 2.01 6.08 1.78 0.97 0.34 0.04 0.06
Current Deferred Revenue		 12 123 108 116 16 1.61 1.01 0.68 0.78
Current Employee Benefit Liabilities		 14 5.71 7.27 7.77 4.60 2.55 2.07 0.63 0.70
Other Current Liabilities		 23 33 26 24 24 7.67 14 3.65 4.49
Total Noncurrent Liabilities		 161 83 80 77 69 57 49 52 51
Other Noncurrent Operating Liabilities		 87 82 79 77 69 57 49 52 51
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -51 -98 -111 -91 -55 -35 -37 -37 -37
Total Preferred & Common Equity		 -51 -98 -111 -91 -55 -35 -37 -37 -37
Total Common Equity		 -51 -98 -111 -91 -55 -35 -37 -37 -37
Common Stock		 1,858 1,903 1,909 1,951 1,961 1,979 1,982 1,989 1,994
Retained Earnings		 -1,909 -2,001 -2,020 -2,042 -2,017 -2,014 -2,018 -2,026 -2,031
Accumulated Other Comprehensive Income / (Loss)		 -0.57 -0.06 -0.01 0.02 0.00 0.00 0.00 0.00 -0.00

Annual Metrics And Ratios for Atara Biotherapeutics

This table displays calculated financial ratios and metrics derived from Atara Biotherapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 28,631,144.00 28,860,635.00 30,595,866.00 45,648,266.00 54,150,553.00 77,714,302.00 88,417,386.00 94,878,670.00 101,922,250.00 - 7,210,235.00
DEI Adjusted Shares Outstanding		 1,145,246.00 1,154,425.00 1,223,835.00 1,825,931.00 2,166,022.00 3,108,572.00 3,536,695.00 3,795,147.00 4,076,890.00 - 7,210,235.00
DEI Earnings Per Adjusted Shares Outstanding		 -49.96 -68.47 -97.64 -126.35 -134.34 -98.64 -96.17 -60.16 -67.73 - 4.53
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 212.55% -86.51% 1,404.02% -6.33%
EBITDA Growth		 -95.34% -41.62% -54.87% -94.28% -24.61% -4.28% -10.60% 31.82% -20.66% 71.14% 148.92%
EBIT Growth		 -104.17% -38.11% -51.20% -93.08% -26.10% -5.38% -10.92% 32.08% -19.60% 69.99% 143.21%
NOPAT Growth		 -107.59% -39.00% -49.59% -95.10% -24.70% -4.52% -10.16% 17.61% 1.61% 69.77% 161.34%
Net Income Growth		 -104.32% -38.15% -51.16% -93.07% -26.13% -5.38% -10.93% 32.88% -20.95% 69.07% 138.28%
EPS Growth		 60.14% -22.77% -45.45% -31.75% -7.59% 26.81% 12.53% 38.29% -20.95% 82.50% 122.52%
Operating Cash Flow Growth		 -112.71% -61.55% -45.78% -105.45% -31.07% 23.29% -22.00% -22.63% 28.64% 64.39% 25.87%
Free Cash Flow Firm Growth		 -78.54% -66.26% -63.81% -85.69% -14.17% 30.12% -26.54% 7.29% 7.72% 56.08% 17.92%
Invested Capital Growth		 -497.00% 61.62% 640.84% 150.84% 8.43% -222.35% -137.96% -26.93% -29.90% 7.40% 66.42%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 59.01% -10.33% 88.75% 28.38% -20.51%
EBITDA Q/Q Growth		 -18.69% 1.53% -16.44% -23.93% 0.83% 0.41% -3.41% 6.66% 6.12% 36.69% 30.47%
EBIT Q/Q Growth		 -21.06% 3.67% -16.69% -24.05% 0.54% 0.15% -3.45% 7.12% 5.36% 36.51% 37.02%
NOPAT Q/Q Growth		 -23.64% 3.58% -16.32% -24.08% 0.71% -0.65% -3.56% 5.99% 5.34% 36.40% 36.70%
Net Income Q/Q Growth		 -23.06% 3.67% -16.68% -24.03% 0.52% -0.93% -3.67% 7.60% 4.87% 35.86% 39.69%
EPS Q/Q Growth		 -136.96% 4.84% -15.27% -13.33% 7.50% 9.39% -3.42% 7.05% 4.87% 36.04% 48.55%
Operating Cash Flow Q/Q Growth		 -20.84% -19.45% -4.51% -22.05% -0.54% 23.19% -15.84% -9.12% 3.25% 27.40% 26.93%
Free Cash Flow Firm Q/Q Growth		 0.00% -17.42% -15.38% -10.14% -1.33% 29.02% -18.50% 2.74% -21.54% 20.34% 29.77%
Invested Capital Q/Q Growth		 -978.53% 73.71% 166.62% -21.78% -10.89% -245.03% -93.77% -46.07% 1.49% 11.37% 6.68%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,617.41% -352.82% -3,156.78% -60.57% 31.63%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,673.85% -441.25% -3,219.48% -64.71% 29.69%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,672.05% -363.32% -3,222.35% -64.30% 29.67%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,672.28% -359.12% -3,220.88% -66.23% 27.07%
Tax Burden Percent		 99.98% 100.01% 99.99% 99.98% 100.00% 100.00% 100.01% 100.01% 100.01% 99.99% 99.91%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 98.84% 99.95% 103.02% 91.32%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.09%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -27.36% -27.79% -55.37% -89.29% -92.43% -81.43% -91.69% -112.39% -2,014.86% 86.92% -48.15%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -853.52% -903.49% -692.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -64.40% -54.70% -101.95% -60.39% 55.40%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -64.41% -54.07% -101.91% -62.20% 50.55%
Return on Common Equity (ROCE)		 -27.36% -27.79% -55.37% -89.29% -92.43% -81.43% -91.69% -112.39% -2,014.86% 86.92% -48.15%
Return on Equity Simple (ROE_SIMPLE)		 -18.16% -31.15% -67.18% -68.08% -100.07% -66.32% -121.65% -180.28% 278.27% 87.79% 0.00%
Net Operating Profit after Tax (NOPAT)		 -41 -57 -85 -166 -207 -216 -238 -196 -193 -58 36
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,171.70% -308.87% -2,253.64% -45.30% 29.67%
Net Nonoperating Expense Percent (NNEP)		 -7.68% -7.69% -16.31% -27.19% -29.52% -23.75% -23.35% -10.40% -56.25% -57.13% -12.28%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - 194.70% 60.04% -93.06%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 387.42% 112.55% 593.82% 30.93% 21.74%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,386.44% 428.69% 2,622.01% 117.48% 31.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,773.85% 541.25% 3,319.48% 164.71% 70.31%
Earnings before Interest and Taxes (EBIT)		 -57 -79 -120 -231 -291 -307 -340 -231 -276 -83 36
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -54 -76 -118 -229 -285 -297 -329 -224 -271 -78 38
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.40 1.62 3.11 4.68 3.07 3.30 4.98 2.46 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 2.40 1.62 3.11 4.68 3.07 3.30 4.98 2.46 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 68.51 4.90 6.10 0.59 1.08
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.99
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 25.06%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 33.48 43.95 20.10 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 50.26 1.07 0.05 0.26 1.01
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.19
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.40
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.40
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.01 -0.98 -0.92 -0.90 -1.01 -1.18 -1.51 -10.76 0.48 0.38
Leverage Ratio		 1.03 1.04 1.12 1.18 1.17 1.24 1.42 2.08 19.77 -1.40 -0.95
Compound Leverage Factor		 1.03 1.04 1.12 1.18 1.17 1.24 1.42 2.05 19.76 -1.44 -0.87
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 46.10 23.37 5.40 14.99 4.95 3.78 -1.58 -6.72 -22.29 -28.23 -126.90
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 33.43 26.93 6.23 8.04 7.43 6.31 3.64 3.74 0.72 0.48 0.82
Quick Ratio		 33.01 26.43 6.01 7.74 7.05 6.05 3.52 3.59 0.60 0.33 0.65
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -36 -60 -99 -183 -209 -146 -185 -172 -158 -70 -57
Operating Cash Flow to CapEx		 -12,812.41% -1,987.58% -432.49% -500.41% -4,228.75% -4,005.30% -2,084.33% -6,449.56% -16,108.26% -27,933.74% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -460.27 -29.98 -15.08 -15.06
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -725.01 -36.51 -14.89 -13.43
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -736.25 -36.74 -14.94 -13.18
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.15 0.03 0.94 1.87
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 18.19 3.09 0.23 7.25 88.32
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.39 2.12 1.69 50.07 176.70
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 20.06 118.29 1,582.30 50.37 4.13
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 20.06 118.29 1,582.30 50.37 4.13
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -5.58 -2.14 12 29 31 -39 -92 -116 -151 -140 -47
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 -0.31 -0.61 -0.06 -0.89 -1.29
Increase / (Decrease) in Invested Capital		 -4.64 3.44 14 17 2.45 -70 -53 -25 -35 11 93
Enterprise Value (EV)		 435 154 387 1,276 633 1,025 1,022 68 0.39 34 122
Market Capitalization		 756 410 554 1,586 892 1,526 1,393 311 52 77 130
Book Value per Share		 $11.01 $8.79 $5.81 $7.42 $5.37 $5.95 $3.16 $1.33 ($0.97) ($16.89) ($5.34)
Tangible Book Value per Share		 $11.01 $8.79 $5.81 $7.42 $5.37 $5.95 $3.16 $1.33 ($0.97) ($16.89) ($5.34)
Total Capital		 315 254 178 339 291 462 280 127 -99 -97 -39
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -321 -256 -166 -310 -259 -501 -371 -243 -52 -43 -8.48
Capital Expenditures (CapEx)		 0.29 3.02 20 36 5.57 4.51 11 4.19 1.20 0.25 -0.95
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.79 -5.00 -22 -28 -23 -60 -92 -27 -92 -112 -11
Debt-free Net Working Capital (DFNWC)		 315 251 145 282 236 440 279 216 -40 -70 -2.71
Net Working Capital (NWC)		 315 251 145 282 236 440 279 216 -40 -70 -2.71
Net Nonoperating Expense (NNE)		 16 22 34 65 84 90 102 32 83 27 3.14
Net Nonoperating Obligations (NNO)		 -321 -256 -166 -310 -259 -501 -371 -243 -52 -43 -8.48
Total Depreciation and Amortization (D&A)		 3.51 2.97 1.69 1.85 5.74 9.16 11 6.68 5.62 4.81 2.38
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -454.41% -42.16% -1,075.80% -87.11% -9.27%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,370.87% 340.02% -470.75% -54.04% -2.24%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,370.87% 340.02% -470.75% -54.04% -2.24%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($56.00) ($68.75) ($100.00) ($131.75) ($141.75) ($103.75) ($90.75) ($56.00) ($65.25) ($11.41) $2.61
Adjusted Weighted Average Basic Shares Outstanding		 1.15M 1.16M 1.55M 1.85M 2.34M 3.34M 3.72M 4.08M 4.24M 7.49M 12.54M
Adjusted Diluted Earnings per Share		 ($56.00) ($68.75) ($100.00) ($131.75) ($141.75) ($103.75) ($90.75) ($56.00) ($65.25) ($11.41) $2.57
Adjusted Weighted Average Diluted Shares Outstanding		 1.15M 1.16M 1.55M 1.85M 2.34M 3.34M 3.72M 4.08M 4.24M 7.49M 12.72M
Adjusted Basic & Diluted Earnings per Share		 ($56.00) ($68.75) ($100.00) ($131.75) ($141.75) ($103.75) ($90.75) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.02M 1.15M 1.19M 1.75M 2.05M 2.96M 3.75M 3.84M 4.77M 5.86M 8.18M
Normalized Net Operating Profit after Tax (NOPAT)		 -41 -57 -85 -166 -207 -216 -238 -196 -193 -58 36
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,171.70% -308.87% -2,253.64% -45.30% 29.67%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,672.05% -359.10% -3,220.70% -66.24% 27.09%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -619.24 -52.27 -17.97 9.45
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -526.43 -36.56 -12.66 9.45
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -630.48 -52.50 -18.02 9.70
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -537.67 -36.78 -12.71 9.70
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Atara Biotherapeutics

This table displays calculated financial ratios and metrics derived from Atara Biotherapeutics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 101,922,250.00 119,359,230.00 120,416,138.00 4,915,049.00 - 5,858,909.00 5,961,391.00 7,023,032.00 7,210,235.00 8,178,114.00 9,010,172.00
DEI Adjusted Shares Outstanding		 4,076,890.00 4,774,369.00 4,816,646.00 4,915,049.00 - 5,858,909.00 5,961,391.00 7,023,032.00 7,210,235.00 8,178,114.00 9,010,172.00
DEI Earnings Per Adjusted Shares Outstanding		 -14.83 -6.65 -3.95 -4.46 - 6.49 0.40 -0.61 -0.47 -0.51 -0.54
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 1,823.98% 2,131.40% 2,892.69% 1,779.79% 670.30% 258.77% -38.63% -91.41% -95.13% -99.47% -96.42%
EBITDA Growth		 23.75% 59.99% 76.17% 70.82% 79.88% 237.29% 120.42% 81.94% 78.26% -108.18% -237.09%
EBIT Growth		 20.68% 58.55% 74.47% 69.55% 79.50% 224.41% 117.65% 83.16% 78.75% -108.69% -246.63%
NOPAT Growth		 20.62% 58.35% 74.47% 68.75% 79.65% 277.40% 125.02% 83.57% 79.00% -106.08% -203.48%
Net Income Growth		 18.94% 57.53% 73.21% 68.61% 79.00% 219.71% 112.53% 80.36% 73.17% -110.91% -302.51%
EPS Growth		 18.94% 57.53% 81.67% 82.13% 88.09% 161.95% 106.13% 89.08% 84.12% -108.29% -268.42%
Operating Cash Flow Growth		 11.38% 22.94% 79.84% 92.23% 51.45% 4.98% 31.25% -145.35% 76.72% 89.08% 54.39%
Free Cash Flow Firm Growth		 74.48% -8.76% -160.43% -142.95% -174.01% -107.24% -570.45% -923.73% -380.42% 30.10% 83.91%
Invested Capital Growth		 -29.90% -2.92% 0.02% -2.92% 7.40% 52.27% 60.79% 68.11% 66.42% 33.87% 18.30%
Revenue Q/Q Growth		 98.88% 543.39% 4.69% 40.33% -18.50% 199.66% -82.09% -80.35% -53.81% -67.65% 22.09%
EBITDA Q/Q Growth		 17.46% 47.49% 43.14% -18.40% 43.07% 458.23% -91.54% -204.72% 31.46% -34.73% -41.77%
EBIT Q/Q Growth		 13.88% 48.01% 41.51% -16.26% 42.02% 415.58% -91.70% -210.90% 26.83% -28.98% -40.10%
NOPAT Q/Q Growth		 13.86% 47.89% 41.66% -19.34% 43.91% 554.24% -91.77% -178.35% 28.29% -31.45% -40.10%
Net Income Q/Q Growth		 13.39% 47.47% 40.01% -15.01% 42.06% 399.46% -93.72% -280.27% 20.85% -21.70% -16.62%
EPS Q/Q Growth		 13.39% 47.47% 45.13% 5.48% 41.98% 305.88% -94.57% -268.42% 15.63% -7.41% -10.34%
Operating Cash Flow Q/Q Growth		 1.83% 41.25% 64.05% 62.53% -513.46% -14.99% 73.99% -33.74% 41.79% 46.06% -8.62%
Free Cash Flow Firm Q/Q Growth		 -128.76% -146.97% 28.04% 15.96% -83.47% -86.78% -132.81% -28.32% 13.90% 72.82% 46.40%
Invested Capital Q/Q Growth		 1.49% 4.24% -1.11% -7.91% 11.37% 50.65% 16.93% 12.23% 6.68% 2.79% -2.62%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -1,332.48% -108.75% -59.07% -49.84% -34.81% 41.62% 19.65% -104.75% -155.42% -647.29% -751.59%
Operating Margin		 -1,410.21% -114.22% -63.66% -54.14% -37.26% 39.53% 18.19% -103.50% -160.69% -652.91% -749.21%
EBIT Margin		 -1,410.49% -113.97% -63.68% -52.75% -37.53% 39.52% 18.32% -103.39% -163.76% -652.91% -749.21%
Profit (Net Income) Margin		 -1,421.68% -116.07% -66.51% -54.51% -38.75% 38.73% 13.58% -124.62% -213.54% -803.29% -767.30%
Tax Burden Percent		 100.02% 100.08% 100.00% 99.92% 99.85% 100.00% 99.87% 100.66% 100.00% 100.00% 100.02%
Interest Burden Percent		 100.78% 101.76% 104.45% 103.41% 103.42% 97.99% 74.25% 119.75% 130.40% 123.03% 102.39%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.13% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -2,014.86% 1,398.03% 350.14% 188.38% 86.92% 20.40% -7.94% -36.80% -48.15% 20.49% 46.33%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -44.63% -16.93% -21.84% -31.97% -35.24% 69.46% 44.82% -181.73% -305.84% -368.32% -160.22%
Return on Assets (ROA)		 -44.98% -17.24% -22.82% -33.03% -36.39% 68.06% 33.24% -219.04% -398.81% -453.16% -164.09%
Return on Common Equity (ROCE)		 -2,014.86% 1,398.03% 350.14% 188.38% 86.92% 20.40% -7.94% -36.80% -48.15% 20.49% 46.33%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 237.12% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -42 -22 -13 -15 -8.54 39 3.19 -2.50 -1.79 -2.36 -3.30
NOPAT Margin		 -987.14% -79.95% -44.56% -37.89% -26.08% 39.53% 18.17% -72.45% -112.48% -457.03% -524.44%
Net Nonoperating Expense Percent (NNEP)		 -12.53% -7.84% -6.65% -7.86% -8.78% -2.62% -2.79% -4.44% -6.31% -15.99% -9.50%
Return On Investment Capital (ROIC_SIMPLE)		 42.30% 22.25% 11.51% 16.82% 8.78% -70.46% -9.11% 6.83% 4.66% 6.32% 8.93%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 269.38% 40.62% 31.12% 25.93% 28.82% 11.69% 37.06% 115.46% 268.15% 697.09% 605.40%
R&D to Revenue		 1,166.51% 166.34% 116.38% 109.29% 87.69% 27.95% 41.59% 84.71% -13.98% 31.78% 213.49%
Operating Expenses to Revenue		 1,515.29% 214.22% 163.66% 154.14% 137.26% 60.47% 81.81% 203.50% 260.69% 752.91% 849.21%
Earnings before Interest and Taxes (EBIT)		 -60 -31 -18 -21 -12 39 3.22 -3.57 -2.61 -3.37 -4.72
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -57 -30 -17 -20 -11 41 3.45 -3.62 -2.48 -3.34 -4.74
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 6.10 2.39 0.66 0.40 0.59 0.17 0.24 0.66 1.08 1.67 16.70
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 7.94 4.30 3.99 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 12.59% 23.25% 25.06% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.05 1.05 0.09 0.00 0.26 0.10 0.13 0.57 1.01 1.31 15.11
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 1.84 2.97 3.19 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 2.78 3.32 3.40 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 2.93 3.32 3.40 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -10.76 7.55 1.83 1.20 0.48 0.39 0.40 0.64 0.38 0.24 0.45
Leverage Ratio		 19.77 -14.01 -3.52 -2.34 -1.40 -1.48 -1.06 -1.36 -0.95 -0.89 -0.80
Compound Leverage Factor		 19.93 -14.26 -3.67 -2.42 -1.45 -1.45 -0.78 -1.63 -1.24 -1.09 -0.82
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -17.98 -17.71 -24.86 -20.25 -26.10 -40.45 -70.30 -88.11 -133.17 -140.44 -134.23
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.72 0.59 0.42 0.59 0.48 0.57 1.70 1.02 0.82 2.16 1.98
Quick Ratio		 0.60 0.45 0.25 0.44 0.33 0.47 1.53 0.87 0.65 1.48 1.49
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -7.20 -18 -13 -11 -20 -37 -86 -110 -95 -26 -14
Operating Cash Flow to CapEx		 -114,559.09% -23,316.54% -36,706.90% 0.00% -27,190.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -6.12 -15.41 -10.13 -9.09 -19.39 -36.22 -88.22 -121.04 -105.97 -31.02 -72.25
Operating Cash Flow to Interest Expense		 -42.86 -25.68 -8.44 -3.37 -24.06 -27.67 -7.53 -10.77 -6.37 -3.70 -17.48
Operating Cash Flow Less CapEx to Interest Expense		 -42.90 -25.79 -8.46 -3.37 -24.15 -27.67 -7.53 -10.72 -5.75 -3.70 -17.48
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.03 0.15 0.34 0.61 0.94 1.76 2.45 1.76 1.87 0.56 0.21
Accounts Receivable Turnover		 0.23 1.92 42.60 134.10 7.25 8.93 0.00 93.55 88.32 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.69 7.85 16.28 31.94 50.07 122.01 151.36 168.06 176.70 136.11 57.09
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 1,582.30 190.53 8.57 2.72 50.37 40.85 0.00 3.90 4.13 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 1,582.30 190.53 8.57 2.72 50.37 40.85 0.00 3.90 4.13 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -151 -145 -146 -158 -140 -69 -57 -50 -47 -46 -47
Invested Capital Turnover		 -0.06 -0.24 -0.43 -0.65 -0.89 -1.87 -1.85 -1.46 -1.29 -0.40 -0.12
Increase / (Decrease) in Invested Capital		 -35 -4.10 0.03 -4.48 11 76 89 108 93 23 10
Enterprise Value (EV)		 0.39 36 5.50 -27 34 21 24 87 122 30 94
Market Capitalization		 52 83 41 40 77 35 46 101 130 39 103
Book Value per Share		 ($0.97) ($0.82) ($0.92) ($18.42) ($16.89) ($9.40) ($5.88) ($5.22) ($5.34) ($4.56) ($4.11)
Tangible Book Value per Share		 ($0.97) ($0.82) ($0.92) ($18.42) ($16.89) ($9.40) ($5.88) ($5.22) ($5.34) ($4.56) ($4.11)
Total Capital		 -99 -98 -111 -91 -97 -55 -35 -37 -39 -37 -37
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -52 -46 -35 -67 -43 -14 -22 -14 -8.48 -8.36 -9.87
Capital Expenditures (CapEx)		 0.04 0.13 0.03 0.00 0.09 0.00 0.00 -0.04 -0.56 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -92 -121 -121 -131 -112 -35 -12 -13 -11 -1.83 -3.19
Debt-free Net Working Capital (DFNWC)		 -40 -74 -86 -64 -70 -21 10 0.38 -2.71 6.53 6.68
Net Working Capital (NWC)		 -40 -74 -86 -64 -70 -21 10 0.38 -2.71 6.53 6.68
Net Nonoperating Expense (NNE)		 18 9.88 6.29 6.68 4.15 0.79 0.81 1.80 1.61 1.79 1.53
Net Nonoperating Obligations (NNO)		 -52 -46 -35 -67 -43 -14 -22 -14 -8.48 -8.36 -9.87
Total Depreciation and Amortization (D&A)		 3.32 1.43 1.32 1.17 0.89 2.05 0.24 -0.05 0.13 0.03 -0.02
Debt-free, Cash-free Net Working Capital to Revenue		 -1,075.80% -347.63% -194.42% -130.88% -87.11% -17.37% -6.42% -8.78% -9.27% -7.92% -51.50%
Debt-free Net Working Capital to Revenue		 -470.75% -213.97% -137.62% -63.84% -54.04% -10.37% 5.41% 0.25% -2.24% 28.21% 107.89%
Net Working Capital to Revenue		 -470.75% -213.97% -137.62% -63.84% -54.04% -10.37% 5.41% 0.25% -2.24% 28.21% 107.89%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($356.75) ($5.75) ($3.10) ($2.93) ($1.70) $3.53 $0.20 ($0.32) ($0.27) ($0.29) ($0.32)
Adjusted Weighted Average Basic Shares Outstanding		 169.44K 5.62M 6.14M 7.47M 7.49M 10.76M 12.20M 13.56M 12.54M 14.08M 15.03M
Adjusted Diluted Earnings per Share		 ($356.75) ($5.75) ($3.10) ($2.93) ($1.70) $3.50 $0.19 ($0.32) ($0.27) ($0.29) ($0.32)
Adjusted Weighted Average Diluted Shares Outstanding		 169.44K 5.62M 6.14M 7.47M 7.49M 10.85M 12.31M 13.56M 12.72M 14.08M 15.03M
Adjusted Basic & Diluted Earnings per Share		 ($356.75) $0.00 $0.00 $0.00 ($1.70) $0.00 $0.00 $0.00 ($0.27) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 4.77M 4.82M 4.92M 5.76M 5.86M 5.96M 7.02M 7.21M 8.18M 9.01M 10.04M
Normalized Net Operating Profit after Tax (NOPAT)		 -42 -22 -13 -15 -8.54 27 3.19 -2.50 -1.79 -2.36 -3.30
Normalized NOPAT Margin		 -987.14% -79.95% -44.56% -37.89% -26.08% 27.67% 18.17% -72.45% -112.48% -457.03% -524.44%
Pre Tax Income Margin		 -1,421.43% -115.98% -66.51% -54.56% -38.81% 38.73% 13.60% -123.81% -213.54% -803.29% -767.14%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -51.00 -27.04 -14.45 -17.92 -12.09 38.14 3.31 -3.93 -2.92 -4.06 -24.71
NOPAT to Interest Expense		 -35.69 -18.97 -10.11 -12.87 -8.40 38.15 3.29 -2.75 -2.01 -2.84 -17.30
EBIT Less CapEx to Interest Expense		 -51.04 -27.15 -14.47 -17.92 -12.18 38.14 3.31 -3.88 -2.30 -4.06 -24.71
NOPAT Less CapEx to Interest Expense		 -35.73 -19.08 -10.14 -12.87 -8.49 38.15 3.29 -2.70 -1.39 -2.84 -17.30
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Atara Biotherapeutics’ financial profile remains highly stressed despite a modest sequential improvement in revenue and lower operating losses from earlier periods. In Q2 2026, revenue increased to $0.63 million from $0.52 million in Q1 2026, but remained far below $17.6 million in Q2 2025, $32.8 million in Q4 2024 and $40.2 million in Q3 2024. The company reported a net loss of $4.83 million, compared with a $4.15 million loss in Q1 2026 and a $2.39 million profit in the restated Q2 2025 results.

Operating expenses rose sequentially to $5.35 million from $3.89 million in Q1, primarily because of higher selling, general and administrative costs. However, research and development expense fell to $1.35 million from $1.64 million. Atara’s operating loss widened to $4.72 million from $3.37 million in the prior quarter, indicating that the small revenue increase was not enough to offset higher overhead.

The balance sheet shows limited financial flexibility. At June 30, 2026, cash and short-term investments totaled approximately $9.87 million, while quarterly operating cash usage was $3.34 million. Total liabilities of $58.02 million exceeded total assets of $21.02 million, leaving shareholders’ equity at negative $37.0 million. The company also raised $4.83 million through common stock issuance during the quarter, which provided liquidity but increased dilution risk.

  • Revenue improved sequentially: Q2 2026 revenue increased approximately 22% from Q1 2026, although the absolute level remains very small.
  • Research and development spending declined: R&D expense fell about 18% sequentially to $1.35 million, potentially reflecting tighter cost controls.
  • Interest expense dropped sharply: Interest expense declined to $0.19 million in Q2 from $0.83 million in Q1 and $0.89 million in Q4 2025.
  • Operating cash burn was lower than in late 2025: Cash used in operating activities was $3.34 million in Q2 2026, compared with $5.70 million in Q4 2025 and $9.79 million in Q3 2025.
  • Additional equity financing provided near-term liquidity: Atara raised $4.83 million through common stock issuance in Q2, following $2.95 million raised in Q1.
  • Cash resources remain concentrated in liquid assets: Cash and short-term investments totaled $9.87 million at quarter-end, but the company also used $6.63 million in investing activities, and the reported net change in cash was negative $5.14 million.
  • Revenue has deteriorated dramatically: Q2 2026 revenue was down approximately 96% from Q2 2025 and more than 98% below Q1 2025’s $98.1 million, based on the restated figures provided.
  • Losses remain persistent: Atara has reported substantial losses in most of the periods supplied, including a $4.83 million loss in Q2 2026 and a $4.15 million loss in Q1 2026.
  • Operating expenses continue to exceed revenue by a wide margin: Q2 operating expenses of $5.35 million were more than eight times revenue, producing a $4.72 million operating loss.
  • Negative equity and ongoing dilution are major risks: Shareholders’ equity was negative $37.0 million, while repeated equity raises—including $4.83 million in Q2—may dilute existing shareholders as the company continues to consume cash.
10/15/26 02:50 AM ETAI Generated. May Contain Errors.

Atara Biotherapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Atara Biotherapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Over the last 10 years, Atara Biotherapeutics' net income changed from -$57.22 million in 2015 to $32.69 million in 2025. Check out Atara Biotherapeutics' forecast to explore projected trends and price targets.

Atara Biotherapeutics' total operating income in 2025 was $35.86 million, based on the following breakdown:
  • Total Gross Profit: $120.77 million
  • Total Operating Expenses: $84.91 million

Over the last 10 years, Atara Biotherapeutics' total revenue changed from $0.00 in 2015 to $120.77 million in 2025, a change of 12,077,200,000.0%.

In the past 11 quarters, Atara Biotherapeutics' cash and equivalents has ranged from $3.22 million in Q2 2026 to $64.79 million in Q3 2023, and is currently $3.22 million as of their latest financial filing in Q2 2026.

Atara Biotherapeutics had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2015.

Over the last 10 years, Atara Biotherapeutics' book value per share changed from 11.01 in 2015 to -5.34 in 2025.


Related Companies

Financial statements for NASDAQ:ATRA last updated on 8/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel